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Rarely has the topic of the Kreb’s cycle ever managed to generate
much enthusiasm or excitement within the biomedical profession.
To most, the complex routing of mitochondrial and cytosolic en-
ergy metabolism pathways has often appeared recondite and de-
tached from the realities of life in clinical medicine. However,
times have changed and we now know that one of the Kreb’s cycle
enzymes, fumarate hydratase (FH, also known as fumarase), is in
fact intricately linked to a constellation of human tumors, both be-
nign and malignant. Speci¢cally, in 2002 Tomlinson et al (2002)
demonstrated that heterogeneous germline mutations in FH pre-
dispose to dominantly inherited skin leiomyomas, uterine ¢broids
and papillary renal cell cancer. Subsequently, other reports have
con¢rmed these ¢ndings (Alam et al, 2003;Toro et al, 2003). In this
issue of the Journal, Martinez-Mir et al (2003) describe 5 further
mutations in the FH gene and outline the biologic and clinical im-
plications of their ¢ndings.
The disorder that results from autosomal dominant mutations
in the FH gene is known as multiple cutaneous and uterine leio-
myomas (MCUL or MCL: OMIM 150800). Overlapping with
this syndrome is another autosomal dominant condition, heredi-
tary leiomyomatosis and renal cell cancer syndrome (HLRCC;
OMIM 605839). This syndrome also results from mutations in the
FH gene. Complicating matters further is the fact that autosomal
recessive FH gene mutations also underlie the disorder, fumarate
de¢ciency (OMIM 136850, 605839). This condition is associated
with progressive encephalopathy, cerebral atrophy, seizures, hypo-
tonia and renal developmental delay. Intriguingly, carriers of FH
de¢ciency occasionally (but only rarely) exhibit leiomyomas.
The FH enzyme catalyzes the conversion of fumarate to malate
in the mitochondrial matrix. It also exists in a cytosolic form
thought to be involved in amino acid metabolism. The enzyme
is a homotetramer, in which residues from 3 chains combine to
form its active catalytic site.This may be relevant to how di¡erent
pathogenic mutations in£uence enzyme activity since dominant
missense mutations would be expected to disrupt nearly all
homotetramers (with only 1/16 composed of totally wild-type
protein). Such changes might therefore be expected to have more
impact than heterozygous nonsense mutations. Nevertheless, the
5 FH gene mutations reported by Martinez-Mir et al in this issue
(Q142X,1081del4, S115I, H275YandV351L) suggest that the inter-
pretation is more complex. From a functional perspective, just
how reduced FH activity leads to proliferative changes in smooth
muscle or kidney cells is also a mystery, although FH most prob-
ably acts as a tumor suppressor in MCUL/HLRCC since loss-of-
heterozygosity studies have shown loss of the wild-type allele in
cutaneous, uterine and renal tumors (Alam et al, 2003).
A natural sequel to the emerging number of FH gene muta-
tions is to try to establish genotype-phenotype correlation, the
aim being to anticipate features such as time of disease onset, se-
verity of disease, relative involvement of skin/uterus and, most
importantly, to identify individuals at risk of renal cancer. Signif-
icantly, the renal cancers in HLRCC are typically aggressive,
mostly consisting of papillary type II renal cell carcinomas. Thus,
early detection is vital. Initial analyses suggesting that the posi-
tion of the mutation within the 10-exon FH gene might have
some clinical relevance have not been borne out. Rather, it
appears that there are certain key residues that form part of the
active site of the FH enzyme and that missense mutations in the
corresponding amino acids usually result in the most biochemical
disturbance to enzyme activity.That said, we still lack full insight
into precisely what the e¡ects of a speci¢c missense, nonsense or
frameshift mutation will be in a particular individual.
The risk of developing renal cancer is clearly a primary concern.
However, the nature of the neoplasia in the kidneys suggests an
in£uence from modifying genes or environmental factors. This in-
terpretation is based on observations that only 15% of cases of
HLRCC are associated with renal malignancy, that the cancer is
solitary and unilateral, and that there is a lack of multifocal renal
disease. Furthermore, of the 11 families with the FH gene mutation
R190H, renal cancer has only occured in a single family.With re-
levance to the Martinez-Mir et al mutations, it should be pointed
out that the missense mutation H275Y has been linked to cancer in
one other case (Toro et al, 2003). Just what the implications should
be for screening the latest asymptomatic individual who also has
this heterozygous mutation is not clear. However, an important
general point about renal cancer screening is that assessment should
involve computerized tomography rather than ultrasound scan-
ning since papillary renal cell carcinomas are often isoechoic.
In summary, the data from Martinez-Mir et al and related
recently published studies raise several important clinico-patholo-
gical issues. First, in MCUL/HLRCC the mean age of onset of
cutaneous leiomyomas is 25 years and for uterine ¢broids, 30
years. Thus, the early age at onset of symptomatic uterine ¢broids
may have a signi¢cant impact on the child-bearing years of
a¡ected women. Secondly, it needs to be emphasized that in
women with early onset of ¢broids it is important to ask about
a family history of renal cancer. Thirdly, mutation screening of
the FH gene (or biochemical assessment of FH enzyme activity)
will identify most families with MCUL/HLRCC and allow for
identi¢cation of presymptomatic a¡ected individuals. Finally, the
accumulating mutation database has yet to provide any practical
genotype-phenotype correlation and therefore appropriate
screening for renal cancer is important to identify the minority
of cases that will su¡er this often life-threatening complication.
Rarely indeed has basic biochemistry had such important
lessons for clinical medicine.
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